acetaminophen has been researched along with zithromax in 20 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 7 (35.00) | 29.6817 |
2010's | 11 (55.00) | 24.3611 |
2020's | 2 (10.00) | 2.80 |
Authors | Studies |
---|---|
Barecki, M; Casciano, CN; Clement, RP; Johnson, WW; Lew, K; Wang, E | 1 |
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Glen, RC; Lowe, R; Mitchell, JB | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Coleman, EJ; Mandell, GL | 1 |
Miller, GP | 1 |
Subedi, Y | 1 |
Feldhausen, D | 1 |
Dagna, L; Della-Torre, E; Della-Torre, F; Kusanovic, M; Ramirez, GA; Scotti, R; Tresoldi, M | 1 |
1 review(s) available for acetaminophen and zithromax
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
19 other study(ies) available for acetaminophen and zithromax
Article | Year |
---|---|
Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.
Topics: 3T3 Cells; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Cell Survival; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flow Cytometry; Humans; Mice; Microsomes, Liver; Mixed Function Oxygenases; Molecular Structure; Substrate Specificity | 2001 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effect of antipyretic agents on uptake, transport, and release of antimicrobial agents by human polymorphonuclear leukocytes.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Bacterial Agents; Aspirin; Aza Compounds; Azithromycin; Biological Transport; Cell Movement; Fluoroquinolones; Humans; Ibuprofen; Microbial Sensitivity Tests; Moxifloxacin; Neutrophils; Quinolines | 2002 |
Warfarin therapy: how the less interesting half just got interesting.
Topics: Acetaminophen; Anticoagulants; Azithromycin; Cimetidine; Cytochrome P-450 Enzyme System; Drug Interactions; Gefitinib; Humans; Omeprazole; Quinazolines; Stereoisomerism; Substrate Specificity; Warfarin | 2010 |
Around Manaslu Ultramarathon: Diarrhea Is Still the King.
Topics: Acetaminophen; Acetazolamide; Altitude; Altitude Sickness; Analgesics, Non-Narcotic; Anti-Bacterial Agents; Antitrichomonal Agents; Azithromycin; Diarrhea; Diuretics; Fatigue; Hand Disinfection; Hand Sanitizers; Headache; Humans; Nausea; Nepal; Rest; Running; Tinidazole; Vomiting | 2017 |
What is causing this patient's extreme exhaustion and headache?
Topics: Acetaminophen; Adult; Ampicillin; Anti-Bacterial Agents; Azithromycin; Cefpodoxime; Ceftizoxime; Ceftriaxone; Dexamethasone; Drug Therapy, Combination; Fatigue; Female; Headache; Humans; Meningitis, Aseptic; Pneumonia; Tomography, X-Ray Computed; Treatment Outcome; Vancomycin; Young Adult | 2020 |
Treating COVID-19 with colchicine in community healthcare setting.
Topics: Acetaminophen; Anti-Inflammatory Agents; Azithromycin; Betacoronavirus; Cohort Studies; Colchicine; Community Health Services; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Fever; Gene Expression; Humans; Immunity, Innate; Inflammasomes; Intensive Care Units; Interleukin-1; Interleukin-6; Italy; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severe Acute Respiratory Syndrome; Time Factors | 2020 |